Matches in Ubergraph for { <http://purl.obolibrary.org/obo/NCIT_C114299> ?p ?o ?g. }
Showing items 1 to 50 of
50
with 100 items per page.
- NCIT_C114299 IAO_0000115 "An antibody-drug conjugate (ADC) consisting of belantamab, an afucosylated, humanized monoclonal antibody, directed against the B-cell maturation antigen (BCMA), conjugated to mafodotin, an auristatin analogue and microtubule inhibitor monomethyl auristatin phenylalanine (MMAF), with potential antineoplastic activity. Upon administration of belantamab mafodotin, the anti-BCMA antibody moiety selectively binds to BCMA on tumor cell surfaces. Upon internalization, the MMAF moiety binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and induces tumor cell apoptosis. In addition, belantamab mafodotin induces antibody-dependent cellular cytotoxicity (ADCC). Altogether, this results in the inhibition of cellular proliferation in tumor cells that overexpress BCMA. BCMA, a receptor for a proliferation-inducing ligand and B-cell activating factor, is a member of the tumor necrosis factor (TNF) receptor superfamily and plays a key role in plasma cell survival; it is found on the surfaces of plasma cells and overexpressed on malignant plasma cells. Afucosylation of the antibody moiety increases ADCC." @default.
- NCIT_C114299 NCIT_A32 NCIT_C1909 @default.
- NCIT_C114299 NCIT_A7 NCIT_C97848 @default.
- NCIT_C114299 NCIT_NHC0 "C114299" @default.
- NCIT_C114299 NCIT_P106 "Pharmacologic Substance" @default.
- NCIT_C114299 NCIT_P107 "Belantamab Mafodotin" @default.
- NCIT_C114299 NCIT_P108 "Belantamab Mafodotin" @default.
- NCIT_C114299 NCIT_P208 "CL471808" @default.
- NCIT_C114299 NCIT_P210 "2050232-20-5" @default.
- NCIT_C114299 NCIT_P302 "adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent." @default.
- NCIT_C114299 NCIT_P319 "DB1041CXDG" @default.
- NCIT_C114299 NCIT_P322 "CTRP" @default.
- NCIT_C114299 NCIT_P322 "FDA" @default.
- NCIT_C114299 NCIT_P322 "GDC" @default.
- NCIT_C114299 NCIT_P329 "758317" @default.
- NCIT_C114299 NCIT_P330 "758317" @default.
- NCIT_C114299 NCIT_P375 "Anti-BCMA Antibody-drug Conjugate GSK2857916" @default.
- NCIT_C114299 NCIT_P375 "Belantamab Mafodotin" @default.
- NCIT_C114299 NCIT_P399 "758317" @default.
- NCIT_C114299 normalizedInformationContent "95.413332725061409" @default.
- NCIT_C114299 referenceCount "2" @default.
- NCIT_C114299 hasExactSynonym "BELANTAMAB MAFODOTIN" @default.
- NCIT_C114299 hasExactSynonym "Belantamab Mafodotin" @default.
- NCIT_C114299 hasExactSynonym "Belantamab Mafodotin-blmf" @default.
- NCIT_C114299 hasExactSynonym "Blenrep" @default.
- NCIT_C114299 hasExactSynonym "GSK2857916" @default.
- NCIT_C114299 hasExactSynonym "J6M0-mcMMAF" @default.
- NCIT_C114299 inSubset NCIT_C116977 @default.
- NCIT_C114299 inSubset NCIT_C116978 @default.
- NCIT_C114299 inSubset NCIT_C128784 @default.
- NCIT_C114299 inSubset NCIT_C157711 @default.
- NCIT_C114299 inSubset NCIT_C157712 @default.
- NCIT_C114299 inSubset NCIT_C176424 @default.
- NCIT_C114299 inSubset NCIT_C177537 @default.
- NCIT_C114299 inSubset NCIT_C63923 @default.
- NCIT_C114299 type Class @default.
- NCIT_C114299 isDefinedBy ncit.owl @default.
- NCIT_C114299 label "Belantamab Mafodotin" @default.
- NCIT_C114299 subClassOf NCIT_C114299 @default.
- NCIT_C114299 subClassOf NCIT_C129821 @default.
- NCIT_C114299 subClassOf NCIT_C129823 @default.
- NCIT_C114299 subClassOf NCIT_C1512 @default.
- NCIT_C114299 subClassOf NCIT_C163758 @default.
- NCIT_C114299 subClassOf NCIT_C181108 @default.
- NCIT_C114299 subClassOf NCIT_C181111 @default.
- NCIT_C114299 subClassOf NCIT_C1908 @default.
- NCIT_C114299 subClassOf NCIT_C1909 @default.
- NCIT_C114299 subClassOf NCIT_C274 @default.
- NCIT_C114299 subClassOf NCIT_C307 @default.
- NCIT_C114299 subClassOf NCIT_C308 @default.